Form 4: Outset Medical CFO Renee Gaeta Receives Significant RSU Grant

Outset Medical, Inc.'s Chief Financial Officer, Renee Gaeta, was granted 131,425 restricted stock units (RSUs) on June 10, 2025, aligning her interests with long-term shareholder value.

Summary

• Renee Gaeta, Chief Financial Officer of Outset Medical, Inc. (OM), was granted 131,425 restricted stock units (RSUs).
• The grant date for these RSUs was June 10, 2025.
• Each RSU represents a contingent right to receive one share of Outset Medical common stock.
• The RSUs will vest in a staggered manner: 33.33% on June 3, 2026, and the remaining 66.67% will vest in equal quarterly installments over the subsequent two years.
• Quarterly vesting dates include February 15th, May 15th, August 15th, and November 15th.
• Vesting is contingent upon Ms. Gaeta's continuous service through each applicable vesting date.
• The acquisition price for these RSUs was reported as $0.0, indicating a grant rather than a purchase.

Sentiment

Score: 7

Explanation: The document reports a standard executive compensation grant, which is generally positive as it aligns management's interests with shareholders and aids in retention. There are no negative financial implications or red flags.

Positives

• The grant of restricted stock units to the Chief Financial Officer aligns her long-term financial interests with those of the company's shareholders, promoting sustained performance.
• This form of equity compensation serves as a strong retention incentive for key executive talent, ensuring continuity in leadership.

Risks

• The RSUs are subject to forfeiture if the reporting person's continuous service to the company is terminated before the vesting dates.

Future Outlook

The vesting schedule for the granted RSUs extends over the next two to three years, indicating a commitment to the Chief Financial Officer's continued service and aligning her incentives with the company's long-term performance and growth.

Industry Context

The grant of restricted stock units to a key executive like the Chief Financial Officer is a common practice in the medical technology and broader corporate sectors. It serves as a standard mechanism for executive compensation, aiming to attract, retain, and incentivize top talent by linking their personal wealth to the company's stock performance.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) as a form of executive compensation is a widely adopted practice across various industries, including medical devices and technology, aligning with global benchmarks for incentivizing long-term performance.
• The vesting schedule, with an initial cliff followed by quarterly installments over two years, is a common structure designed to ensure executive retention and sustained commitment, comparable to practices seen in companies like Medtronic, Intuitive Surgical, or other publicly traded medical device firms.

Related Party Transactions

• This document details an equity compensation grant to Renee Gaeta, the Chief Financial Officer, which is a transaction between the company and an insider, typical for executive remuneration.

Stakeholder Impact

• Shareholders: The RSU grant aligns the Chief Financial Officer's financial incentives with shareholder value creation, potentially leading to more focused long-term strategic decisions.
• Employees: This grant demonstrates the company's commitment to executive retention and competitive compensation practices, which can positively influence overall employee morale and talent attraction.
• Management: The Chief Financial Officer receives a significant equity stake, increasing her personal investment in the company's success.

Next Steps

• The RSUs will begin vesting on June 3, 2026, with subsequent quarterly vesting events on February 15th, May 15th, August 15th, and November 15th over the following two years, subject to continuous service.

Key Dates

Keywords

Outset Medical, OM, Renee Gaeta, Chief Financial Officer, Restricted Stock Units, RSU Grant, Executive Compensation, Insider Transaction, SEC Form 4, Equity Compensation, Vesting Schedule